Iinuma Koji, Enomoto Torai, Kawada Kei, Fujimoto Shota, Ishida Takashi, Takagi Kimiaki, Nagai Shingo, Ito Hiroki, Kawase Makoto, Nakai Chie, Kawase Kota, Kato Daiki, Takai Manabu, Nakane Keita, Kameyama Koji, Koie Takuya
Department of Urology, Gifu University Graduate School of Medicine, Gifu 5011194, Japan.
Department of Urology, Matsunami General Hospital, Hashima-gun 5016062, Japan.
J Clin Med. 2021 Nov 16;10(22):5325. doi: 10.3390/jcm10225325.
The aim of this study was to assess the utility of neutrophil-to-lymphocyte ratio (NLR), plate-let-to-lymphocyte ratio (PLR), and systemic immune inflammation index (SII) as predictive biomarkers with oncological outcomes for metastatic renal cell carcinoma (mRCC) patients treated with nivolumab and ipilimumab (NIVO + IPI). We conducted a retrospective multicenter cohort study assessing patients with mRCC treated with NIVO + IPI at eight institutions in Japan. In this study, the follow-up period was median 14 months. The 1-year overall- and progression-free survival (PFS) rates were 89.1% and 63.1, respectively. The objective response rate (ORR) and disease control rate (DCR) were 41.9% and 81.4%, respectively. The 1-year PFS rates were 85.7% and 49.1% for NLR ≤ 2.8 and >2.8, respectively ( = 0.005), and 75.5% and 49.7% for PLR ≤ 215.6 and >215.6, respectively ( = 0.034). Regarding SII, the 1-year PFS rates were 90.0% and 54.8% when SII was ≤561.7 and >561.7, respectively ( = 0.023). Therefore, NLR, PLR, and SII levels in mRCC patients treated with NIVO + IPI may be useful in predicting oncological outcomes.
本研究旨在评估中性粒细胞与淋巴细胞比值（NLR）、血小板与淋巴细胞比值（PLR）以及全身免疫炎症指数（SII）作为接受纳武单抗和伊匹单抗（NIVO + IPI）治疗的转移性肾细胞癌（mRCC）患者肿瘤学预后预测生物标志物的效用。我们进行了一项回顾性多中心队列研究，评估日本8家机构中接受NIVO + IPI治疗的mRCC患者。在本研究中，随访期的中位数为14个月。1年总生存率和无进展生存率（PFS）分别为89.1%和63.1%。客观缓解率（ORR）和疾病控制率（DCR）分别为41.9%和81.4%。NLR≤2.8和>2.8的患者1年PFS率分别为85.7%和49.1%（P = 0.005），PLR≤215.6和>215.6的患者分别为75.5%和49.7%（P = 0.034）。关于SII，当SII≤561.7和>561.7时，1年PFS率分别为90.0%和54.8%（P = 0.023）。因此，接受NIVO + IPI治疗的mRCC患者的NLR、PLR和SII水平可能有助于预测肿瘤学预后。
